FIP Statement of Policy on Counterfeit Medicines
(2003; 4 pages) [French] [Spanish]


The FIP is seriously concerned about the continuing, even increasing, risk to public health represented by counterfeiting of medicines, particularly in countries where legislation governing the manufacture and distribution of medicines, or the enforcement of legislation, is ineffective. The massive circulation of poor quality, harmful and counterfeit active ingredients and finished products in international commerce can seriously reduce the quality of patient care.

El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019